Compare Pfizer Inc (PFE) vs Schlumberger NV (SLB) Price & Performance

Pfizer (PFE) trades at $24.75, down 1.2% on the day, with a neutral technical outlook. The company maintains strong fundamentals with consistent earnings beats, including Q1 2026 EPS of $0.75 beating expectations of $0.722. Pfizer demonstrates robust profitability with a 73.51% gross margin and 11.83% net income margin, though revenue has moderated from pandemic peaks. Recent news highlights the company's focus on AI drug discovery and pipeline development.

Pfizer presents a value opportunity trading below analyst consensus target of $28.25, with 38% of analysts rating it Buy. The stock offers a solid dividend yield with recent $0.43 payments. Key risks include patent expirations and revenue normalization post-COVID, while catalysts include obesity and oncology pipeline developments in 2026.

SLB trades at $46.59, down 0.85% on the day, with a bearish technical signal despite recent earnings beats. The company maintains strong profitability with a 9.26% net margin and 14.57% ROE, supported by $6.5B in operating cash flow. Recent strategic moves include a partnership with Liberty Energy for data center power solutions and major contract wins like the Baleine Phase 3 EPC award, positioning SLB to capitalize on energy and AI infrastructure demand.

The outlook is cautiously optimistic with an 84.85% analyst buy rating and a $62.83 consensus price target implying 35% upside. Risks include oil price volatility and execution challenges in new ventures, but SLB's solid balance sheet and digital growth initiatives offer a compelling case for long-term investors amid near-term market weakness.